Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capmatinib + spartalizumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Capmatinib is a small molecule MET inhibitor that targets dysregulated MET signaling in cancer cells. Spartalizumab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), an immune checkpoint receptor. The combination of capmatinib and spartalizumab has been investigated for its potential to provide synergistic clinical benefit by simultaneously inhibiting oncogenic MET signaling and enhancing anti-tumor immune responses through PD-1 blockade[2][3][5]. This combination has been studied in advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations, as well as in advanced hepatocellular carcinoma (HCC) after prior sorafenib treatment[1][2][3].
- Brand names
- Tabrecta
- Other names
- capmatinib and spartalizumabINC280 and PDR001INC-280 and PDR001INC 280 and PDR001capmatinib plus spartalizumab
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on capmatinib + spartalizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capmatinib + spartalizumab.